Opioid supply crunch for U.S. coronavirus patients prompts appeal to relax limits
Opioid supply crunch for U.S. coronavirus patients prompts appeal to relax limits
Reuters
COVID-19
opioids
opioid crisis
Flag link:
Sanofi and Regeneron's Dupixent shows more encouraging results
Sanofi and Regeneron's Dupixent shows more encouraging results
Reuters
Sanofi
Dupixent
atopic dermatitis
clinical trials
Flag link:
Trump administration uses wartime powers to be first in line on medical supplies
Trump administration uses wartime powers to be first in line on medical supplies
MedCity News
Donald Trump
regulatory
medical supplies
COVID-19
Flag link:
Axon's Tau Vaccine Shows Promise in Phase II Alzheimer's Study
Axon's Tau Vaccine Shows Promise in Phase II Alzheimer's Study
BioSpace
Axon Neurosciences
Alzheimer's disease
clinical trials
vaccines
Flag link:
Coronavirus Testing Backlogs Continue As Laboratories Struggle To Keep Up With Demand
Coronavirus Testing Backlogs Continue As Laboratories Struggle To Keep Up With Demand
NPR
Quest Diagnostics
diagnostics
COVID-19
Flag link:
EMA Recommends Remdesivir for Treatment of COVID-19 Under Compassionate-Use Rules
EMA Recommends Remdesivir for Treatment of COVID-19 Under Compassionate-Use Rules
Motley Fool
Gilead Sciences
Europe
COVID-19
remdesivir
Flag link:
The long path to an effective coronavirus vaccine
The long path to an effective coronavirus vaccine
EP Vantage
vaccines
COVID-19
coronaviruses
Moderna Therapeutics
Shenzhen Genoimmune
Cansino Biologics
Pfizer
BioNTech
Inovio
JNJ
Altimmune
Heat Biologics
iBio
EpiVax
Flag link:
April 3 2020 - GSK allies with Innovax for COVID-19 vaccine R&D project
Flag link:
GSK allies with Innovax for COVID-19 vaccine R&D project
GSK allies with Innovax for COVID-19 vaccine R&D project
Fierce Biotech
GSK
Xiamen Innovax Biotech
vaccines
COVID-19
Flag link:
Sanofi CEO: Amid COVID-19 supply push, one fever means 'maybe a half dozen' workers off the job
Sanofi CEO: Amid COVID-19 supply push, one fever means 'maybe a half dozen' workers off the job
Fierce Pharma
Sanofi
COVID-19
Paul Hudson
Plaquenil
hydroxychloroquine
drug manufacturing
Flag link:
Some pharmas acting like “toilet roll profiteers” on COVID-19, says clinician
Some pharmas acting like “toilet roll profiteers” on COVID-19, says clinician
Pharmaforum
transparency
COVID-19
pandemic
patents
artificial intelligence
Flag link:
J&J inks Fate deal to move into allogeneic CAR therapies
J&J inks Fate deal to move into allogeneic CAR therapies
Fierce Biotech
JNJ
Fate Therapeutics
CAR NK
CAR-T
cell therapies
drug development
Flag link:
Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline
Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline
AP
Servier
R&D
Symphogen
antibodies
Flag link:
Zentalis Pharmaceuticals Raises $165 Million in Expanded IPO
Zentalis Pharmaceuticals Raises $165 Million in Expanded IPO
Bloomberg
Zentalis
cancer
oncology
IPOs
Flag link:
Drug discovery in the age of coronavirus
Drug discovery in the age of coronavirus
Endpoints
COVID-19
drug discovery
drug development
Flag link:
AstraZeneca on expanding its diabetes research franchise
AstraZeneca on expanding its diabetes research franchise
Pharmaforum
AstraZeneca
diabetes
Flag link:
Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19
Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19
Pharmaceutical Business Review
Vir Biotechnology
Alnylam
COVID-19
RNAi
drug development
Flag link:
Ahead of US IPO, Legend Biotech adds $150M, top-tier investors to back CAR-T pipeline
Ahead of US IPO, Legend Biotech adds $150M, top-tier investors to back CAR-T pipeline
Endpoints
Nanjing Legend Biotech
GenScript
IPOs
Flag link:
GSK's asthma biologic Nucala is one step closer to approval in key chronic rhinosinusitis population
GSK's asthma biologic Nucala is one step closer to approval in key chronic rhinosinusitis population
Endpoints
GSK
Nucala
rhinosinusitis
nasal polyps
clinical trials
Flag link:
Neuroscience Specialty Sales Representative (Redding, CA)
Flag link:

Pages